Metraipolis › archive › dc_61e728cd44ba

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer — Europe PMC PMID:42067541

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42067541
DOI
10.1038/s41392-[numero omesso]-w
License (as archived)
solo-consultazione
Archived
2026-11-02T22:50:45.914Z
SHA-256 of the archived text
c1c9f3cb11962b55c74ad04c767e578b1ddbfbac048ed237eb376eeffede4210
Stable URL of this page
https://metraipolis.com/documento/dc_61e728cd44ba

How to cite

Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer — Europe PMC PMID:42067541 — Europe PMC (en), https://europepmc.org/article/MED/42067541 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_61e728cd44ba (Metraipolis archive dc_61e728cd44ba, sha256 c1c9f3cb11962b55c74ad04c767e578b1ddbfbac048ed237eb376eeffede4210)
BibTeX
@misc{dc61e728cd44ba,
  title = {Single-cell imaging analysis, therapeutic modeling and a Phase Ib trial validate BCL-2 as a target across heterogeneous castration-resistant prostate cancer — Europe PMC PMID:42067541},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42067541},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_61e728cd44ba; sha256 c1c9f3cb11962b55c74ad04c767e578b1ddbfbac048ed237eb376eeffede4210},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42067541. Agents can read the archived copy with the MCP tool read_document.